Producer
Aurobindo Pharma
India's second-largest pharma company by revenue; major manufacturer of SSRIs, antipsychotic APIs, and finished formulations for the US and EU markets
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Aurobindo Pharma supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Aurobindo Pharma makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Antibiotics (Semi-Synthetic Penicillins + Cephalosporins)
30%CNS / SSRIs + Antipsychotics (US Market)
25%Antiretrovirals (Global HIV Programs)
20%Injectable + Oncology
15%APIs (Bulk Actives)
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Aurobindo Pharma is publicly known in the US as the company behind generic Lexapro (escitalopram) and generic Seroquel (quetiapine) — a supplier of mental health medications to US pharmacies. The same Hyderabad manufacturing complex simultaneously produces tenofovir, lamivudine, and dolutegravir — the antiretroviral drugs dispensed to HIV patients in Uganda, Kenya, Tanzania, and dozens of other Sub-Saharan African countries through PEPFAR (US President's Emergency Plan for AIDS Relief) and the Global Fund. At the height of the HIV epidemic, the price difference between branded ARV and Aurobindo generic ARV was the difference between receiving treatment or dying for millions of patients in low-income countries. A single FDA manufacturing quality action against Aurobindo (they received multiple Form 483 observations in 2019) simultaneously creates a shortage risk for US mental health prescriptions and HIV treatment continuity for Sub-Saharan African patients — two populations with no clinical overlap but a shared supply chain in Hyderabad, India.
Aurobindo Pharma ↗Origin2023
Aurobindo Pharma was founded in 1986 in Hyderabad by P.V. Ramprasad Reddy, who had previously worked at Cipla (the Indian pharma company that first challenged HIV drug patent monopolies in 2001). Aurobindo started by manufacturing semi-synthetic penicillin intermediates (7-ADCA, 6-APA) for export at a time when penicillin API production was rapidly shifting from Europe and the US to India and China due to environmental regulations on fermentation waste. By the mid-1990s, Aurobindo had leveraged antibiotic API expertise to enter finished generics for the US market. The timing was critical: the Hatch-Waxman Act (1984) had created the US generic drug approval pathway, and Indian companies with low-cost API manufacturing were positioned to exploit it. Aurobindo is a case study in how US pharmaceutical regulation (enabling generics) combined with Indian industrial policy (pharma export support) transferred critical drug API manufacturing from the US and Europe to India over roughly 20 years.
Aurobindo Pharma ↗